Octapharma USA, Inc. Supports HTRS Blood Disorders Educational Initiatives at Annual Scientific Symposium
4/2/2013 11:25:14 AM
More...
|
FDA Approves Octaplas® Expanding Octapharma USA, Inc.'s Transfusion Medicine Therapies
1/18/2013 8:02:53 AM
More...
|
Octapharma USA, Inc. Expands Access to octagam® 5% for Participating 340B Healthcare Facilities
6/25/2012 12:29:25 PM
More...
|
Octapharma USA, Inc. Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events
2/27/2012 12:16:06 PM
More...
|
Octapharma USA, Inc. Appoints Global Biopharmaceutical Executive David E. Holliday as Vice President of Commercial Development
1/11/2012 11:08:59 AM
More...
|
Octapharma USA, Inc. Announces Octagam® 5% Again Available for U.S. Purchase
11/30/2011 11:28:58 AM
More...
|
Octapharma USA, Inc. Release: First Clinical Study Comparing Pharmacokinetic Profiles of VWF/FVIII Products Published in Medical Journal
11/7/2011 2:26:32 PM
More...
|
FDA Approves U.S. Market Return for Octapharma USA, Inc.'s Octagam(R) Following Octapharma's Implementation of Enhanced Safety Measures
11/4/2011 11:15:30 AM
More...
|
Octapharma USA, Inc. to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH
10/18/2011 12:37:37 PM
More...
|
Octapharma USA, Inc. to Participate in Important Medical Meetings at AABB, NHF, ASHP and ASH
10/18/2011 12:10:57 PM
More...
|
|